Browse our 650+ Publications​

Latest Publications

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Palmer CD, et al.
Nature Medicine
August 2022
Authors and Affiliates
Christine D Palmer 1, Amy R Rappaport 1, Matthew J Davis 1, Meghan G Hart 1, Ciaran D Scallan 1, Sue-Jean Hong 1, Leonid Gitlin 1, Lauren D Kraemer 1, Sonia Kounlavouth 1, Aaron Yang 1, Lindsey Smith 1, Desiree Schenk 1, Mojca Skoberne 1, Kiara Taquechel 1, Martina Marrali 1, Jason R Jaroslavsky 1, Charmaine N Nganje 1, Elizabeth Maloney 1, Rita Zhou 1, Daniel Navarro-Gomez 1, Adrienne C Greene 1, Gijsbert Grotenbreg 1, Renee Greer 1, Wade Blair 1, Minh Duc Cao 1, Shawn Chan 1, Kyounghwa Bae 1, Alexander I Spira 2, Sameek Roychowdhury 3, David P Carbone 3, Brian S Henick 4, Charles G Drake 4, Benjamin J Solomon 5, Daniel H Ahn 6, Amit Mahipal 7, Steve B Maron 8, Benny Johnson 9, Raphael Rousseau 1, Roman Yelensky 1, Chih-Yi Liao 10, Daniel V T Catenacci 10, Andrew Allen 1, Andrew R Ferguson 1, Karin Jooss 11; 1 Gritstone bio, Inc., Emeryville, CA, USA. 2 Virginia Cancer Specialists, Virginia Cancer Specialists, VA, Fairfax, USA. 3 The Ohio State University Medical Center, Columbus, OH, USA. 4 Columbia University Medical Center, New York, NY, USA. 5 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6 Mayo Clinic, Phoenix, AZ, USA. 7 Mayo Clinic Cancer Center, Rochester, MN, USA. 8 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 11 Gritstone bio, Inc., Emeryville, CA, USA. kjooss@gritstone.com.

The RAG1 Ubiquitin Ligase Domain Stimulates Recombination of TCRβ and TCRα Genes and Influences Development of αβ T Cell Lineages

Burn TN, et al.
Journal of Immunology
August 2022
Authors and Affiliates
Thomas N Burn 1,2, Charline Miot 3, Scott M Gordon 1,4, Erica J Culberson 3, Tamir Diamond 1,5, Portia A Kreiger 3, Katharina E Hayer 6, Anamika Bhattacharyya 7, Jessica M Jones 7, Craig H Bassing 8,3,9, Edward M Behrens 8,2; 1 Penn Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 2 Division of Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA. 3 Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA. 4 Division of Neonatology, The Children's Hospital of Philadelphia, Philadelphia, PA. 5 Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA. 6 Department of Biomedical and Health Bioinformatics, The Children's Hospital of Philadelphia, Philadelphia, PA. 7 Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC; and. 8 Penn Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; bassing@chop.edu behrens@chop.edu. 9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

Hoyos V, et al.
August 2022
Authors and Affiliates
Valentina Hoyos 1, Spyridoula Vasileiou 2, Manik Kuvalekar 2, Ayumi Watanabe 2, Ifigeneia Tzannou 2, Yovana Velazquez 2, Matthew French-Kim 2, Wingchi Leung 2, Suhasini Lulla 2, Catherine Robertson 2, Claudette Foreman 3, Tao Wang 3, Shaun Bulsara 3, Natalia Lapteva 2, Bambi Grilley 2, Matthew Ellis 3, Charles Kent Osborne 3, Angela Coscio 3, Julie Nangia 3, Helen E Heslop 2, Cliona M Rooney 2, Juan F Vera 2, Premal Lulla 2, Mothaffar Rimawi 3, Ann M Leen 2; 1 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, 1102 Bates Ave, Feigin Center 17th Floor. Houston, TX 77030, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA. 3 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Ruck T, et al.
August 2022
Authors and Affiliates
Tobias Ruck 1,2, Sumanta Barman 2, Andreas Schulte-Mecklenbeck 1, Steffen Pfeuffer 1, Falk Steffen 3, Christopher Nelke 1, Christina B Schroeter 2, Alice Willison 2, Michael Heming 1, Thomas Müntefering 2, Nico Melzer 1, Julia Krämer 1, Maren Lindner 1, Marianne Riepenhausen 1, Catharina C Gross 1, Luisa Klotz 1, Stefan Bittner 3, Paolo A Muraro 4, Tilman Schneider-Hohendorf 1, Nicholas Schwab 1, Gerd Meyer Zu Hörste 1, Norbert Goebels 2, Sven G Meuth 1 2, Heinz Wiendl 1; 1 Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, 48149 Muenster, Germany. 2 Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany. 3 Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. 4 Department of Brain Sciences, Imperial College London, London, UK.

Symptom burden and immune dynamics 6 to 18 months following mild SARS-CoV-2 infection -a case-control study

Fjelltveit EB, et al.
August 2022
Authors and Affiliates
Elisabeth B Fjelltveit 1,2, Bjørn Blomberg 3,4, Kanika Kuwelker 3,5, Fan Zhou 1, Therese B Onyango 1, Karl A Brokstad 1,6, Rebecca Elyanow 7, Ian M Kaplan 7, Camilla Tøndel 3,8,9, Kristin G I Mohn 1,5, Türküler Özgümüş 10, Rebecca J Cox 1,2, Nina Langeland 3,4, Bergen COVID-19 Research Group; 1 Influenza Centre, Department of Clinical Science, University of Bergen; Bergen, Norway. 2 Department of Microbiology, Haukeland University Hospital; Bergen, Norway. 3 Department of Clinical Science, University of Bergen; Bergen, Norway. 4 National Advisory Unit for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital; Bergen, Norway. 5 Department of Medicine, Haukeland University Hospital, Bergen, Norway. 6 Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway. 7 Adaptive Biotechnologies, Seattle, WA, USA. 8 Department of Research and Development, Haukeland University Hospital, Bergen, Norway. 9 Department of Pediatrics, Haukeland University Hospital, Bergen, Norway. 10 Department of Global Public Health and Primary Care, University of Bergen; Bergen, Norway.

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Kim SP, et al.
Cancer Immunology Research
August 2022
Authors and Affiliates
Sanghyun P Kim 1, Nolan R Vale 1, Nikolaos Zacharakis 1, Sri Krishna 1, Zhiya Yu 1, Billel Gasmi 2, Jared J Gartner 1, Sivasish Sindiri 1, Parisa Malekzadeh 1, Drew C Deniger 1, Frank J Lowery 1, Maria R Parkhurst 1, Lien T Ngo 1, Satyajit Ray 1, Yong F Li 1, Victoria Hill 1, Maria Florentin 1, Robert V Masi 1, Biman C Paria 1, Noam Levin 1, Alakesh Bera 1, Elizabeth A Hedges 1, Agnes Choi 1, Praveen D Chatani 1, Anup Y Parikh 1, Shoshana Levi 1, Samantha Seitter 1, Yong-Chen Lu 1, Zhili Zheng 1, Todd D Prickett 1, Li Jia 3, Jonathan M Hernandez 4, Chuong D Hoang 5, Paul F Robbins 1, Stephanie L Goff 1, Richard M Sherry 1, James C Yang 1, Steven A Rosenberg 1; 1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2 Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland. 3 National Institutes of Health Library, Office of Director, National Institutes of Health, Bethesda, Maryland. 4 Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5 Thoracic Surgery Branch, National Cancer Institute, NIH, CCR and The Clinical Center, Bethesda, Maryland.

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Fix SM, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Samantha M Fix 1, Marie-Andrée Forget 1, Donastas Sakellariou-Thompson 1, Yunfei Wang 1, Tamara M Griffiths 2, Minjung Lee 3, Cara L Haymaker 3, Ana Lucía Dominguez 1, Rafet Basar 4, Christopher Reyes 5, Sanjay Kumar 5, Larissa A Meyer 6, Patrick Hwu #,7, Chantale Bernatchez #,1, Amir A Jazaeri #,6; 1 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2 Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3 Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4 Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA. 6 Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Patrick.Hwu@moffitt.org. # Contributed equally.

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

Kremenovic M, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Mirela Kremenovic 1,2, Alfred A Chan 3, Bing Feng 4, Lukas Bäriswyl 1, Steve Robatel 1,2, Thomas Gruber 1, Li Tang 4, Delphine J Lee 3, Mirjam Schenk 5; 1 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland. 2 Graduate School Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. 3 Division of Dermatology, Department of Medicine, The Lundquist Institute, Torrance, California, USA. 4 Institute of Bioengineering and Institute of Materials Science and Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, VD, Switzerland. 5 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland mirjam.schenk@pathology.unibe.ch.

High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments

Fernandez N, et al.
August 2022
Authors and Affiliates
Nicolas Fernandez 1, Deepak Perumal 2, Adeeb Rahman 3, Seunghee Kim-Schulze 3, Jen Yesil 4, Daniel Auclair 4, Homer Adams 3rd 5, Samir Parekh 6, Sacha Gnjatic 7, Hearn Jay Cho 8; 1 Precision Immunology Institute. 2 Tisch Cancer Institute. 3 Human Immune Monitoring Center. 4 Multiple Myeloma Research Foundation, Norwalk, CT. 5 Janssen Research & Development, LLC, Spring House, PA. 6 Precision Immunology Institute; Tisch Cancer Institute; Department of Oncological Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY. 7 Precision Immunology Institute; Tisch Cancer Institute; Human Immune Monitoring Center. 8 Precision Immunology Institute; Tisch Cancer Institute; Multiple Myeloma Research Foundation, Norwalk, CT. Electronic address: hearn.jay.cho@mssm.edu.
Previous Next